Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a “AMBITION” clincal trial for treatment of advanced NASH.
CRV431 is a cyclophillin inhibitor. The compound has been used in nonclinical pharmacology study using the STAMTM mouse model and has been shown to improve liver fibrosis.
For detail information, see the Hepion pharma's press release.
http://irdirect.net/prviewer/release/id/4362811